尽管原发性脑肿瘤的分子谱分析和分类取得了重大进展，但对于大多数患者来说，个性化治疗仍然有限。在这里，我们在德国弗莱堡分子肿瘤委员会的现实环境中探讨了个体分子分析的可行性以及生物标志物引导治疗对成年原发性脑癌患者的疗效。我们分析了 102 名患有 21 种脑肿瘤类型的患者的基因图谱、个性化治疗建议和临床结果。细胞周期、BRAF 和 mTOR 通路的改变最常导致个性化治疗建议。 71% 的患者被推荐采用分子信息疗法，32% 的患者已完成分子诊断，并实施了该疗法。靶向治疗后的疾病控制率为 50%，总体缓解率为 30%，31% 的患者无进展生存期 2/1 比率至少为 1.3。这项研究强调了分子引导治疗的有效性以及脑癌生物标志物分层试验的必要性。© 2024。作者。

Despite major advances in molecular profiling and classification of primary brain tumors, personalized treatment remains limited for most patients. Here, we explored the feasibility of individual molecular profiling and the efficacy of biomarker-guided therapy for adult patients with primary brain cancers in the real-world setting within the molecular tumor board Freiburg, Germany. We analyzed genetic profiles, personalized treatment recommendations, and clinical outcomes of 102 patients with 21 brain tumor types. Alterations in the cell cycle, BRAF, and mTOR pathways most frequently led to personalized treatment recommendations. Molecularly informed therapies were recommended in 71% and implemented in 32% of patients with completed molecular diagnostics. The disease control rate following targeted treatment was 50% and the overall response rate was 30%, with a progression-free survival 2/1 ratio of at least 1.3 in 31% of patients. This study highlights the efficacy of molecularly guided treatment and the need for biomarker-stratified trials in brain cancers.© 2024. The Author(s).